Salveen Richter

Q: What is Salveen Richter's success rate?

Salveen Richter currently has a success rate of 83.44534765673605.

Q: What is the average return of Salveen Richter's calls?

Their stock ratings have generated an average return of 59.391512419520815.

Goldman Sachs | Healthcare

Salveen Richter is an analyst from Goldman Sachs specializing in the Healthcare sector. Ranked #234 out of 4588 analysts, they have issued 17 stock ratings with a success rate of 83.45% and an average return of 59.39%.

With 17 ratings to date, Salveen Richter is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 83.45% and an average return of 59.39%, highlighting promising potential as their track record develops further.

#234

Out of 4588

Total Ratings

+83.45%

Success Rate

+59.39%

Average Return

Recent Ratings Analysis

RARE

Hold

Mar 24, 2026

Target

$25.00

Current

$18.50

Performance

0.00%

Salveen Richter rated RARE as Neutral on Mar 24, 2026, setting a price target of 25. The Hold stance appears justified, as shares hovered around 18.5 with a 0.00% move.

QURE

Hold

Mar 03, 2026

Target

$37.00

Current

$15.18

Performance

68.11%

On Mar 03, 2026, QURE was given a Neutral rating by Salveen Richter, with a target price of 37. The stock rallied from 15.18 to 15.18 after the Hold rating, surprising to the upside.

MRNA

Hold

Feb 17, 2026

Target

$41.00

Current

$51.34

Performance

16.87%

MRNA received a Neutral rating from Salveen Richter on Feb 17, 2026, aiming for 41. Investors saw gains of 16.87% that the cautious stance didn’t fully capture.

AGIO

Hold

Nov 20, 2025

Target

$25.00

Current

$28.35

Performance

15.38%

On Nov 20, 2025, Salveen Richter published a Neutral outlook on AGIO, with a target of 25. The Hold call missed some of the bullish momentum as shares advanced toward 25.

FOLD

Hold

Nov 05, 2025

Target

$11.00

Current

$14.41

Performance

56.80%

Salveen Richter on Nov 05, 2025 assigned FOLD a Neutral rating, with a price target of 11. Shares outperformed expectations, climbing 56.80% despite the neutral view.

RCUS

Hold

Oct 30, 2025

Target

$16.00

Current

$20.25

Performance

0.30%

On Oct 30, 2025, Salveen Richter reaffirmed RCUS with a Neutral rating, targeting 16. The neutral call matched muted market action of 0.30%.

IONS

Hold

Sep 26, 2025

Target

$65.00

Current

$69.68

Performance

8.72%

IONS was rated Neutral by Salveen Richter on Sep 26, 2025, with a price objective of 65. Despite caution, upside momentum rewarded risk-takers with gains to 69.68.

APLS

Sell

Sep 26, 2025

Target

$18.00

Current

$17.23

Performance

-22.98%

On Sep 26, 2025, Salveen Richter initiated coverage on APLS with a Sell rating and target of 18. Shares gained despite the bearish call, moving higher from 17.23.

IMNM

Buy

Sep 22, 2025

Target

$26.00

Current

$20.21

Performance

106.86%

Salveen Richter issued a Buy recommendation for IMNM on Sep 22, 2025, price target set at 26. Investors following the Buy call captured upside momentum, with shares now at 20.21.

ALNY

Buy

Sep 16, 2025

Target

$566.00

Current

$308.05

Performance

-33.21%

On Sep 16, 2025, ALNY was evaluated by Salveen Richter, who gave a Buy rating and target of 566. Investors saw limited payoff as shares fell short of the 566 target.

FDMT

Buy

Aug 12, 2025

Target

$38.00

Current

$9.18

Performance

49.27%

Salveen Richter rated FDMT as Buy on Aug 12, 2025, setting a price target of 38. The call has proven timely, with shares rising 49.27% toward the price target of 38.

ACAD

Sell

Aug 07, 2025

Target

$17.00

Current

$20.96

Performance

-14.10%

On Aug 07, 2025, ACAD was given a Sell rating by Salveen Richter, with a target price of 17. The bearish stance was challenged as the stock rebounded from 20.96.

SRPT

Hold

Aug 07, 2025

Target

$19.00

Current

$17.61

Performance

-1.95%

SRPT received a Neutral rating from Salveen Richter on Aug 07, 2025, aiming for 19. Shares remained flat at 17.61, aligning with the neutral rating.

ELVN

Buy

Jun 16, 2025

Target

$37.00

Current

$31.15

Performance

34.91%

On Jun 16, 2025, Salveen Richter published a Buy outlook on ELVN, with a target of 37. Shares gained 34.91%, underscoring the accuracy of the bullish outlook toward 37.

ADPT

Buy

Mar 21, 2025

Target

$9.00

Current

$13.90

Performance

65.48%

Salveen Richter on Mar 21, 2025 assigned ADPT a Buy rating, with a price target of 9. The Buy call aligned well with market performance, producing a gain of 65.48%.

SMMT

Buy

Feb 28, 2025

Target

$42.00

Current

$15.54

Performance

-24.89%

On Feb 28, 2025, Salveen Richter reaffirmed SMMT with a Buy rating, targeting 42. Shares slid 24.89% despite the recommendation, highlighting downside risks.

RLAY

Buy

Feb 27, 2025

Target

$18.00

Current

$9.44

Performance

190.46%

RLAY was rated Buy by Salveen Richter on Feb 27, 2025, with a price objective of 18. A bullish response from the market helped close the gap of 8.56 to the target.

BIIB

Buy

Feb 13, 2025

Target

$245.00

Current

$183.94

Performance

32.86%

On Feb 13, 2025, Salveen Richter initiated coverage on BIIB with a Buy rating and target of 245. The stock’s climb of 32.86% since the call highlights the foresight in the rating.

CRSP

Hold

Feb 13, 2025

Target

$57.00

Current

$46.43

Performance

6.76%

Salveen Richter issued a Neutral recommendation for CRSP on Feb 13, 2025, price target set at 57. A neutral call gave way to stronger-than-expected performance, closing in on 57.

GILD

Hold

Feb 12, 2025

Target

$96.00

Current

$138.11

Performance

33.69%

On Feb 12, 2025, GILD was evaluated by Salveen Richter, who gave a Neutral rating and target of 96. Investors who stayed in despite the Hold saw upside of 33.69%.

DNLI

Buy

Jan 28, 2025

Target

$40.00

Current

$20.97

Performance

-10.77%

Salveen Richter rated DNLI as Buy on Jan 28, 2025, setting a price target of 40. The stock has underperformed, dropping 10.77% despite the bullish target of 40.

NTLA

Hold

Jan 14, 2025

Target

$12.00

Current

$12.81

Performance

31.52%

On Jan 14, 2025, NTLA was given a Neutral rating by Salveen Richter, with a target price of 12. The stock rallied from 12.81 to 12.81 after the Hold rating, surprising to the upside.

SAGE

Hold

Jul 26, 2024

Target

$11.00

Current

$8.68

Performance

-21.02%

SAGE received a Neutral rating from Salveen Richter on Jul 26, 2024, aiming for 11. The Hold stance proved prudent, with the market softening by 21.02%.

Frequency Asked Questions

Who is Salveen Richter?

Salveen Richter is an analyst from Goldman Sachs specializing in the Healthcare sector.

What is Salveen Richter's success rate?

Salveen Richter currently has a success rate of +83.45%.

How many ratings has Salveen Richter issued?

Salveen Richter has issued 17 stock ratings so far.

What is the average return of Salveen Richter's calls?

Their stock ratings have generated an average return of +59.39%.

What is Salveen Richter's ranking?

Salveen Richter is ranked #234 out of 4588 analysts.

What types of ratings does Salveen Richter give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Salveen Richter?

You can follow Salveen Richter by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Salveen Richter?

Their latest rating was a Hold on RARE issued on 2026-03-24.